ЭЛИ-Висцеро-Тест-24 (антитела к 24 антигенам основных органов и систем человека)

ELI-Viscero-Test-24 (antibodies to 24 antigens of major human organs and systems), also known as the ELI test, is used to screen for early organ‑specific immune activity and to guide targeted diagnostic workups within preventive health programs. The autoantibody profile can prioritize follow‑up testing when routine laboratory studies are unrevealing and support integration into structured checkups. It is applied to localize probable tissue involvement in diagnostically challenging cases, to contextualize genetic testing results when assessing early expression of chronic noncommunicable disease risk, and to track response to recovery or treatment protocols. The panel may also be incorporated into preconception evaluation of couples to tailor diagnostic strategies related to conditions that can affect reproductive health.

This panel belongs to the ELI family of multiparametric screening ELISA systems designed to quantify IgG autoantibodies against diverse cellular components from multiple organs and tissues. Natural IgG autoantibodies are present in healthy individuals, participate in clearance of metabolic byproducts, and contribute to regulation of cellular functions. Shifts in specific autoantibody levels—either higher or lower—can accompany disease processes and point toward involvement of particular organs or tissues. ELI-Viscero assesses antibodies to 24 antigens spanning key systems, including the nervous system (e.g., S100B, GFAP, MBP), myocardium, liver, kidneys, lungs, gastric and intestinal mucosa, thyroid, pancreas (including insulin and insulin receptor), adrenal glands, organs of the pelvis, platelets, and vascular endothelium, as well as antigens associated with inflammatory activity (e.g., double‑stranded DNA, β2‑glycoprotein, Fc‑IgG). The format also incorporates evaluation of individual immunoreactivity. Because specific autoantibodies may emerge well before overt pathology, the profile can reveal early changes with potential prognostic relevance. Results are reported as quantitative antibody levels and a graphical profile. Interpretation is individualized and performed by clinicians experienced with ELI tests.